- The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's AUTL AUTO1 (obecabtagene autoleucel, obe-cel).
- The Company's CAR T cell therapy is being investigated in the ongoing FELIX Phase 1b/2 study in relapsed/refractory adult B-cell Acute Lymphocytic Leukemia (ALL) in patients 18 years and older.
- Price Action: AUTL shares are up 5.11% at $6.38 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
